Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

253

Full text

212

Free full text

95

Publication Types

Journal Article

254

Research Support, Non-U.S. Gov't

127

Review

98

Clinical Trial, Phase II

85

Multicenter Study

53

Randomized Controlled Trial

34

Clinical Trial, Phase I

33

Clinical Trial

24

Comparative Study

17

Research Support, N.I.H., Extramural

15

Clinical Trial, Phase III

11

Systematic Review

3

Research Support, U.S. Gov't, P.H.S.

3

Evaluation Study

3

Comment

2

Editorial

2

Meta-Analysis

1

Research Support, N.I.H., Intramural

1

Practice Guideline

1

Historical Article

1

Clinical Trial, Phase IV

1

Observational Study

1

Clinical Trial Protocol

1

Publication Year

From

To

Quick links

Individual year

2025

1

2023

3

2022

5

2021

2

2020

4

2019

4

2018

3

2017

4

2016

5

2015

6

2014

9

2013

9

2012

12

2011

11

2010

18

2009

20

2008

16

2007

24

2006

19

2005

26

2004

15

2003

16

2002

16

2001

4

2000

5

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Pemetrexed""[mesh_terms]

257 Results

Searching titles within these results

Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.

Hieronymus J Derijks, Nikki de Rouw, Berber Piet, Michel M van den Heuvel, Rob Ter Heine

Drug safety 2022;44(12):1271-1281

Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.

A A Adjei

Annals of oncology : official journal of the European Society for Medical Oncology 2001;11(10):1335-41

Biochemical pharmacology of pemetrexed.

Alan Hilary Calvert

Oncology (Williston Park, N.Y.) 2005;18(13 Suppl 8):13-7

An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer.

Giorgio Scagliotti

Expert opinion on pharmacotherapy 2006;6(16):2855-66

Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

J Green, Y Dundar, S Dodd, R Dickson, T Walley

The Cochrane database of systematic reviews 2007;2007(1):CD005574

Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.

Hilary Calvert

Seminars in oncology 2003;30(2 Suppl 3):2-5

Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.

Paul A Bunn, Benjamin Solomon

Future oncology (London, England) 2007;1(6):733-46

Pemetrexed (Alimta): a novel multitargeted antifolate agent.

Alex A Adjei

Expert review of anticancer therapy 2003;3(2):145-56

The role of pemetrexed in the treatment of gastrointestinal malignancy.

Howard S Hochster

Clinical colorectal cancer 2004;4(3):190-5

The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.

Axel-Rainer Hanauske

Lung cancer (Amsterdam, Netherlands) 2004;45 Suppl 1():S121-4

Pemetrexed therapy for malignant pleural mesothelioma.

Katarzyna Puto, Jody S Garey

The Annals of pharmacotherapy 2005;39(4):678-83

Predictive markers for haematological toxicity of pemetrexed.

S J Clarke, S C H Kao, V H Phan

Current drug targets 2010;11(1):48-57

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.

A R Hanauske, V Chen, P Paoletti, C Niyikiza

The oncologist 2001;6(4):363-73

Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis.

Wenzhe Duan, Wenwen Liu, Shengkai Xia, Yang Zhou, Mengyi Tang, Mingxin Xu, Manqing Lin, Xinyu Li, Qi Wang

Journal of translational medicine 2023;21(1):547

Pemetrexed for the treatment of non-small cell lung cancer.

Carlo Genova, Erika Rijavec, Anna Truini, Simona Coco, Claudio Sini, Giulia Barletta, Maria Giovanna Dal Bello, Angela Alama, Grazia Savarino, Paolo Pronzato, Francesco Boccardo, Francesco Grossi

Expert opinion on pharmacotherapy 2014;14(11):1545-58

Results: 1 – 15 / 257

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.